George H. Talbot - Concepedia

Author

George H. Talbot

Also Known As

G H Talbot, G TALBOT, G. H. Talbot, G. Talbot, G.H Talbot, G.H. Talbot, G. H. Talbot, GEORGE H. TALBOT, George H Talbot, George H. Talbot

146

Publications

13.7K

Citations

H-Index

Concepts

All Affiliations

University of Pennsylvania Hospital of the University of Pennsylvania Healthcentric Advisors Clinical Research Institute Foothill Family Clinic

About

George H. Talbot is an author at University of Pennsylvania specializing in medicine, infection control, and clinical microbiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	38	3K
2	Health Sciences	15	15	1.7K
3	Public Health	2	2	293
4	Arts	1	1	23
5	Engineering	1	1	62

George H. Talbot

Publications

6.5K

Citations

H-Index

Page 1

	Year	Citations
10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America Helen W. Boucher, George H. Talbot, Daniel K. Benjamin, Clinical Infectious Diseases Systemic AntibioticsAntimicrobial ChemotherapyAntibiotic ResistanceUnited StatesInfectious Diseases Society	2013	692
Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection Helen W. Boucher, Mark Wilcox, George H. Talbot, New England Journal of Medicine	2014	420
Risk factors for nosocomial candidemia: A case-control study in adults without leukemia James L. Bross, George H. Talbot, Greg Maislin, The American Journal of Medicine Clinical EpidemiologyClinical MycologyRisk FactorsPublic HealthCase-control Study	1989	276
Integrated Analysis of CANVAS 1 and 2: Phase 3, Multicenter, Randomized, Double‐Blind Studies to Evaluate the Safety and Efficacy of Ceftaroline versus Vancomycin plus Aztreonam in Complicated Skin and Skin‐Structure Infection G. Ralph Corey, Mark H. Wilcox, George H. Talbot, Clinical Infectious Diseases	2010	236
The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium Robert C. Moellering, Peter K. Linden, J. F. Reinhardt, Journal of Antimicrobial Chemotherapy Antimicrobial SusceptibilityHealth SciencesAntibioticsVref InfectionVancomycin-resistant Enterococcus Faecium	1999	220
CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections Mark H. Wilcox, G. Ralph Corey, George H. Talbot, Journal of Antimicrobial Chemotherapy	2010	212
FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia Thomas M. File, Donald E. Low, Paul B. Eckburg, Journal of Antimicrobial Chemotherapy	2011	196
Integrated Analysis of FOCUS 1 and FOCUS 2: Randomized, Doubled‐Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil versus Ceftriaxone in Patients with Community‐Acquired Pneumonia Thomas M. File, Donald E. Low, Paul B. Eckburg, Clinical Infectious Diseases	2010	185
FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia Donald E. Low, Thomas M. File, Paul B. Eckburg, Journal of Antimicrobial Chemotherapy	2011	185
CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections G. Ralph Corey, Mark H. Wilcox, George H. Talbot, Journal of Antimicrobial Chemotherapy	2010	160

Page 1